New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 12, 2014
16:14 EDTCYCCCyclacel Pharmaceuticals reports Q2 EPS (22c), consensus (30c)
Reports cash and cash equivalents totaled $33.5M as of June 30. The company said, "We are pleased to report that we have enrolled over 70% of the required number of patients in our Phase 3 SEAMLESS trial in front-line AML. At present we have approximately 90 study centers open for enrollment in the US and Europe with additional sites to be added. We expect to complete SEAMLESS enrollment around the end of 2014 with data readout in the second half of 2015. Having surpassed enrollment of 300 patients, we expect the study's Data Safety Monitoring Board to perform the fourth periodic safety review once 60 days of follow-up have been observed."
News For CYCC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
07:06 EDTCYCCCyclacel Pharmaceuticals CYC065 data shows selectivity, activity
Cyclacel Pharmaceuticals announced the presentation of preclinical data demonstrating the therapeutic potential of CYC065, Cyclacel's second-generation cyclin dependent kinase, or CDK, inhibitor, to treat acute leukemias, and in particular those with rearrangements in the mixed lineage leukemia, or MLL, gene. The data showed that in vitro all human acute myelogenous leukemia, or AML, and acute lymphocytic leukemia, or ALL, cell lines with MLL rearrangements, or MLLr, tested were sensitive to CYC065 and that the drug inhibited MLL-driven gene expression. Potent anticancer activity of CYC065 was demonstrated in vivo in AML xenograft models resulting in over 90% inhibition of tumor growth. The data were presented at the 2014 Society of Hematologic Oncology meeting taking place September 17-20, 2014 in Houston, Texas.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use